Netupitant/Palonosetron Hydrochloride

Phase 3Small molecule

UUniversity of Rochester NCORP Research Base

Netupitant/Palonosetron Hydrochloride is one of 43 small molecule programs targeting Nausea and vomiting. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Nausea and VomitingActive, not recruiting

CancerNot yet recruiting

Nausea and VomitingPhase 3

Active, not recruiting

CancerPhase 1

Not yet recruiting

Competition

Competitive Landscape

224 competitors in Nausea and Vomiting

#DrugCompanyPhaseTrials

Netupitant/Palonosetron Hydrochloride

UUniversity of Rochester NCORP Research Base

Phase 3

1 2

Aloxi

AAvyxa

Preclinical

27 3

Alfenta

Alnylam Pharmaceuticals

Preclinical

1 4

Ramosetron

Astellas

Preclinical

15 5

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

7 6

Phenergan

BBassett Healthcare

Preclinical

5 7

Haldol

DDePuy Orthopaedics

Preclinical

3 8

Anerem

AAcacia Pharma Ltd

Preclinical

2 9

Cytoxan

BBaxter Healthcare Corporation

Preclinical

2 10

Adriamycin

GGynecologic Oncology Group

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 1Not yet recruiting

Cancer

NCT07662200

Clinical

Trials by Indication[1]

Nausea and vomiting1 trial

Treatment of Refractory Nausea and Vomiting in Patients With Breast Cancer

Completed·UUniversity of Rochester NCORP Research Base·Phase 3·NCT03367572·1,363 enrolled

Cancer1 trial

A Pilot Feasibility Study of a Steroid-Sparing Anti-Nausea and Vomiting Regimen With Netupitant/Palonosetron for Patients With Germ Cell Tumours Receiving Multi-Day Cisplatin-Based Chemotherapy at The Ottawa Hospital

Not yet recruiting·OOttawa Hospital Research Institute·Phase 1·NCT07662200·10 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Netupitant/Palonosetron Hydrochloride. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Netupitant/Palonosetron Hydrochloride compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Netupitant/Palonosetron Hydrochloride. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Rochester NCORP Research Base company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: UUniversity of Rochester NCORP Research Base

Netupitant/Palonosetron Hydrochloride

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Nausea and vomiting1 trial

Cancer1 trial

References

Drug Info

Quick Facts

Related News